<SEC-DOCUMENT>0001144204-16-078315.txt : 20160202
<SEC-HEADER>0001144204-16-078315.hdr.sgml : 20160202
<ACCEPTANCE-DATETIME>20160202073020
ACCESSION NUMBER:		0001144204-16-078315
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160201
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160202
DATE AS OF CHANGE:		20160202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		161379184

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v430330_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">of the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):&nbsp;&nbsp;February
1, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SYNTHETIC BIOLOGICS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 31.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nevada</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1-12584</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Commission File No.)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(IRS Employer Identification <BR>
No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>9605 Medical Center Drive, Ste. 270</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rockville, MD 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;(Address
of principal executive offices and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>617 Detroit Street, Ste. 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ann Arbor, MI 48104</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;(Mailing
Address and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code:&nbsp;(734) 332-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 52.8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 52.8pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.02. Termination of a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 1, 2016, Synthetic Biologics,
Inc.&rsquo;s subsidiary, Putney Drug, Inc., f/k/a General Fiber, Inc.(&ldquo;Putney Drug) provided written notice to The Regents
of the University of California (the &ldquo;Regents&rdquo;) that it was terminating its (i) License Agreement with The Regents,
dated as of July 11, 2005, as amended on November 8, 2005, January 3, 2007, August 29, 2007, December 31, 2012, July 25, 2014 and
July 8, 2015 (collectively, the &ldquo;License Agreement&rdquo;) and (ii) Clinical Trial Agreement with The Regents, dated April
29, 2010, as amended July 8, 2015 (collectively, the &ldquo;CTA&rdquo;). Pursuant to the terms of the License Agreement, Putney
Drug, had licensed from The Regents issued method of treatment patents in the U.S. for multiple sclerosis therapy with Trimesta
and Trimesta combination therapies. Based upon the independent third party analysis of the investigator-sponsored Phase 2 clinical
trial that evaluated Trimesta as a treatment for relapsing-remitting multiple sclerosis in women, it was determined that the License
Agreement and the CTA should be terminated. In accordance with the termination provisions of the License Agreement and the CTA,
the terminations will be effective May 2, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the press
release issued by the Company regarding this matter is filed herewith as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 52.8pt">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01.&nbsp; Financial Statements
and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 52.8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibits</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 52.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following exhibit is being
filed as part of this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 52.8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="width: 87%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-indent: 52.8pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 53.9pt 0pt 52.8pt; text-align: center"><B>Description</B>&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">99.1</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Press Release issued February 2, 2016</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 52.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 62.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 52.8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="width: 66%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: February 2, 2016</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 27%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 52.8pt">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 52.8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="width: 87%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-indent: 52.8pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Description</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">99.1</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Press Release issued February 2, 2016</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v430330_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: windowtext"><B>Synthetic
Biologics Reports Results of Independent Third Party Evaluations of </B></FONT><B>Trimesta<SUP>TM</SUP><FONT STYLE="color: windowtext">
Data from</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Investigator-Sponsored Phase 2 Clinical
Trial for Relapsing-Remitting Multiple Sclerosis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Data Analysis Did Not Demonstrate
Statistically Significant Differences</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Between Treatment and Placebo Groups
--</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, February 2, 2016 &ndash;
</B><FONT STYLE="color: Blue"><U>Synthetic Biologics, Inc.</U></FONT> (NYSE MKT: SYN), a clinical stage company focused on developing
therapeutics to protect the gut microbiome, today reported independent third party analysis of the investigator-sponsored Phase
2 clinical trial that evaluated Trimesta as a treatment for relapsing-remitting multiple sclerosis (RRMS) in women (NCT00451204).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2015, Synthetic Biologics disclosed
its intention to conduct independent third party analysis of the Phase 2 RRMS clinical trial data for purposes of evaluating Trimesta&rsquo;s
potential further development. Evaluations were conducted by two independent clinical research organizations. Both the clinical
and magnetic resonance imaging (MRI) results from the independent analyses did not demonstrate statistically significant differences
between the Trimesta plus Copaxone treatment group compared to the Copaxone plus placebo group at either 12 or 24 months. On the
basis of these findings, the Company has decided to terminate its license and clinical trial agreements relating to Trimesta with
the Regents of the University of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Third
Party Analysis of </B></FONT><B>Trimesta<FONT STYLE="color: windowtext"> Data from </FONT>Investigator-Sponsored Phase 2 RRMS Clinical
Trial</B> (differences between the Trimesta plus Copaxone treatment group compared to the Copaxone plus placebo group)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical Analysis:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Annualized relapse rate at 24 months 0.17
vs. 0.25 (p=0.302)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Annualized relapse rate at 12 months 0.13
vs. 0.19 (p=0.252)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MRI Analysis:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Brain Volumes &ndash; change from baseline
in patients without enhancing lesions at baseline</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Whole brain at 12 months -0.34 vs. -0.48 (p=0.321) and 24 months -0.70 vs. -0.79 (p=0.686)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Whole gray matter at 12 months -0.44 vs. -0.70 (p=0.130) and 24 months -0.92 vs. -0.98 (p=0.772)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Cortical gray matter at 12 months -0.36 vs. -0.76 (p=0.071) and 24 months -0.93 vs. -1.12 (p=0.487)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">White matter at 12 months -0.18 vs. -0.15 (p=0.879) and 24 months -0.38 vs. -0.48 (p=0.713)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Enhancing lesion volume &ndash; odds ratio
(OR) for treatment effect</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">OR 1.35 at 12 months (p=0.46)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">OR 1.39 at 24 months (p=0.43)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total T2 lesion volume &ndash; change
from baseline</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">29% vs. 27% at 12 months (p=0.54)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">25% vs. 23% at 24 months (p=0.67)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are disappointed with the outcome
of the data analyses which did not demonstrate statistically significant treatment effects in this study,&rdquo; said Jeffrey Riley,
Chief Executive Officer of Synthetic Biologics. &ldquo;We intend to focus the Company&rsquo;s resources on its other programs,
including our two Phase 2 gut microbiome programs which have both demonstrated positive topline clinical results.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a clinical stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The
Company's lead candidates in Phase 2 development include: (1) SYN-004 which is designed to protect the gut microbiome from the
effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated
diarrhea (AAD), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to
treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). In collaboration with Intrexon Corporation (NYSE:
XON), the Company is developing a preclinical stage monoclonal antibody for the prevention and treatment of Pertussis, and discovery
stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics&rsquo;
website at <FONT STYLE="color: Blue"><U>www.syntheticbiologics.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><I>This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In
some cases, forward-looking statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot;
&quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot;
&quot;estimates,&quot; and similar expressions, and include statements regarding Synthetic Biologics&rsquo; intention to focus
its resources on its other programs including its two Phase 2 gut microbiome programs and the future clinical outcomes of those
product candidates</I></FONT>.<FONT STYLE="color: windowtext"><I> These forward-looking statements are based on management's expectations
and assumptions as of the date of this press release and are subject to risks and uncertainties that could cause actual results
to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual
results to differ materially from current expectations include, among others, a failure to receive the necessary regulatory approvals
for commercialization of Synthetic Biologics&rsquo; therapeutics, a failure of Synthetic Biologics&rsquo; clinical trials, and
those conducted by investigators, to be commenced or completed on time or to achieve desired results, a failure of Synthetic Biologics&rsquo;
clinical trials to receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market or sell its products,
Synthetic Biologics&rsquo; inability to maintain material licensing agreements, or a failure by Synthetic Biologics or its strategic
partners to successfully commercialize products and other risks and uncertainties described in Synthetic Biologics&rsquo; Annual
Report on Form 10-K for the year ended December 31, 2014 and its other filings with the SEC, including subsequent periodic reports
on Forms 10-Q and 8-K. The information in this press release is provided only as of the date of this press release, and Synthetic
Biologics undertakes no obligation to revise or update any forward-looking statements contained in this press release, except as
required by law.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Kris Maly, Vice President, Corporate Communication,
(734) 332-7800, <FONT STYLE="color: Blue"><U>info@syntheticbiologics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Manager, Corporate Communication, (240)
660-2000, <FONT STYLE="color: Blue"><U>info@syntheticbiologics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KCSA Strategic Communications (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lewis Goldberg, Managing Partner, (212) 896-1216, <FONT STYLE="color: Blue"><U>lgoldberg@kcsa.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caitlin Kasunich, Account Director, (212) 896-1241, <FONT STYLE="color: Blue"><U>ckasunich@kcsa.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 1T# 2(  A$! Q$!_\0
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M /772U[V&H6Q%2MW=E^%_P 3Y[$UO]GI4>RN_P ;?@%%%%=YYX4444 %%%%
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M0P_$>E7=_P#8;JP,7VJRG$R)*2%?C!!(Z4WP[I=]9SZC?:B85N;Z4.8X22J
M# &3UK>HI>RCS\_7^E^17UF?LO8Z6_&U[V^_4YWQ#I%]=:A9:CIZV\LMNLD;
MP7!(21'&#3_"FC7.BV-S#=" -+<&4"#[H! X [8Z5OT4*C%3]IU&\54='V+M
M;\='?]7T,*XTRZD\:V>I*BFUBM'B9MPR&)R.*G\2:3)K6B36<,BI*2KH6Z94
MYP:UJ*?LHVDNY/UB:E":WC:WRN_U,#1[37'U:6_U:6*)/)$4=M!(S)G.2QSW
MJ[K4&IS6B-I-PD5Q'('VR#Y95'52<<?A6E10J:4>6[_4)5VZBJ66G2VGW'/>
M&]&N["[U&^O$MX'O'4BWMR2B8!Y^IS70T44X04(\J)K5959\\M_\M!" P((!
M!X(->;>*O"4NGR/?:?&7LSR\:\F+Z>J_RKTJBLL1AH5X\LOO-<)BZF%GS0VZ
MKN>#;\]Z7?7J&L^!M.U-FFMR;.X;DF,91C[K_ABN.O/ >NVK'RHXKI!WB?!_
M(XKPJN7UJ;VNO(^JP^9X6LOBY7V?^>Q@;Z-]73X;UU6P=)NL^R9K1L/ NN7C
MCS84M(^[2MD_D*QCA:LG91?W'3/$X>"O*:^]&+;Q37=Q';VZ&2:0[44=S7L.
M@:2NBZ3%:@AI/O2L/XF/7_#\*KZ#X8L=!0M%F6Y88>=QS] .PK;KVL#@O8>_
M/XG^!\SF>8K$OV=/X5^(U45-VU0-QR<=S3J**]$\@**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
